Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta VirusGlobeNewsWire • Thursday
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026GlobeNewsWire • 10/05/26
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceGlobeNewsWire • 09/10/26
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive PicksZacks Investment Research • 09/09/26
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor ProgramGlobeNewsWire • 09/08/26
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?Zacks Investment Research • 09/07/26
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep goingZacks Investment Research • 09/03/26
Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great ChoiceZacks Investment Research • 08/20/26
Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a BetZacks Investment Research • 08/20/26
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish SignalSeeking Alpha • 08/16/26
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/13/26
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent UpdatesGlobeNewsWire • 08/13/26
Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market AppreciatesSeeking Alpha • 07/18/26
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26